ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1842

Systemic Lupus Erythematosus and Chikungunya Fever: Interactions during the 2014 Outbreak in Martinique

Bastien Bigeard1, Katlyne Polomat2, Emilie Javelle3, Serge ARFI2, Lauren Brunier-Agot4, Florence MOINET2, Fatiha Najioullah5, Elodie Curlier6, Andre Cabié7, Michel DeBandt1, Georges Jean Baptiste2 and Christophe Deligny2, 1internal medicine and rheumatology, Zobda Quitman Hospital, Fort de France, Martinique, 2Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, 3Tropical and Infectious Diseases, Laveran Military Teaching Hospital, Marseille, France, 4Internal medicine and rheumatology, Zobda Quitman Hospital, Fort de France, Martinique, 5virology, Zobda Quitman Hospital, Fort de France, Martinique, 6infectiology, dermatology and internal medicine, CHU de Guadeloupe, Pointe à Pitre, Guadeloupe, 7infectious disease, Zobda Quitman Hospital, Fort de France, Martinique

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: infection and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: There is no data in the literature about chikungunya fever (chik) and SLE. Martinique (French West Indies) experienced for the first time an outbreak of chik during the year 2014 that was an opportunity to study the relation between SLE and this viral infection.

Methods: The main objective was to describe the evolution of Chik patients with SLE. We also searched to know (1) if chik could modify SLE disease activity, (2) the role of SLE treatments, particularly immunosuppressive drugs, during the Chik episode. We perform a retrospective, monocentric, systematic evaluation of all SLE patients (fulfilling 1997 ACR criteria) followed in the internal medicine and rheumatology unit of the University hospital, between january 2014 and may 2015, assessing (1) SLE activity, (2) the presence of signs compatible with a chik episode. A systematic viral serology was prescribed with their usual biological follow up for all patients. Chik severity was considered if an encephalopathy, myocarditis, hepatitis, or multiorgan failure was present.

Results:

167 patients were screened for chik by serology, and we had a result for 110 in may 2015. 56 were included with a positive serology for chik (female: 53; male: 3). Their basic parameters were: mean age at serology (46.5 years, range: 23-81), time since SLE diagnosis to chik episode (12.9 years), renal involvement (42.8%), treatment by immunosuppressant drugs (33.9%), hydroxychloroquine or chloroquine (86.8%), prednisone (64.8%), rituximab (n=3). Clinical signs compatible with a Chik episode were found in 82.6% of the patients with a positive serology. Four patients (7%), all younger than 55 years and one treated by mycophénolate, exhibit severe signs of chik including encephalopathy (n=4) associated with bullous cutaneous lesions (n=3), kidney involvement (n=2). One of these 4 patients who was not immunosuppressed, died in a context of systemic capillary leak syndrome and multiorgan failure. Six of 56 positive patients (10.7%) experienced a lupus flare, all after a symptomatic chik fever: 5/6 were on prednisone, 5/6 hydroxychloroquine and 3/6 (50%) immunosuppressive drugs.

Conclusion: SLE can lead to severe Chik infection and should be considered as a group at risk. Chik fever can probably induce SLE flare. Immunosuppressive drugs seem not influence the clinical picture of chik.


Disclosure: B. Bigeard, None; K. Polomat, None; E. Javelle, None; S. ARFI, None; L. Brunier-Agot, None; F. MOINET, None; F. Najioullah, None; E. Curlier, None; A. Cabié, None; M. DeBandt, None; G. Jean Baptiste, None; C. Deligny, None.

To cite this abstract in AMA style:

Bigeard B, Polomat K, Javelle E, ARFI S, Brunier-Agot L, MOINET F, Najioullah F, Curlier E, Cabié A, DeBandt M, Jean Baptiste G, Deligny C. Systemic Lupus Erythematosus and Chikungunya Fever: Interactions during the 2014 Outbreak in Martinique [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/systemic-lupus-erythematosus-and-chikungunya-fever-interactions-during-the-2014-outbreak-in-martinique/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-lupus-erythematosus-and-chikungunya-fever-interactions-during-the-2014-outbreak-in-martinique/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology